Clinicopathological features, biochemical and molecular markers in 5 patients with adrenocortical carcinoma

Endocrine Journal

Volumn 58, Issue 7, 2011, Pages 527-534

  Kouyama, Ryuji ^a   Hiraishi, Kiichiro ^a   Sugiyama, Toru ^a   Izumiyama, Hajime ^a   Yoshimoto, Takanobu ^a   Akashi, Takumi ^a   Kihara, Kazunori ^a   Homma, Keiko ^b   Shibata, Hirotaka ^c   Hirata, Yukio ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b KEIO UNIVERSITY HOSPITAL   (Japan)

^c KEIO UNIVERSITY   (Japan)

Author keywords

Adrenocortical carcinoma (ACC); Disorganized steroidogenic enzymes; Insulin like growth factor (IGF) II; Urinary steroid metabolites

Indexed keywords

17 HYDROXYPREGNENOLONE; 3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; CORTICOSTEROID; CORTODOXONE; ESTROGEN; HORMONE PRECURSOR; HYDROXYPROGESTERONE; KI 67 ANTIGEN; MESSENGER RNA; MITOTANE; PRASTERONE; PRASTERONE SULFOTRANSFERASE; SOMATOMEDIN B; STEROID 17ALPHA MONOOXYGENASE; SULFOTRANSFERASE; UNCLASSIFIED DRUG;

ADRENAL CORTEX CARCINOMA; ADRENALECTOMY; ADULT; ARTICLE; CANCER RECURRENCE; CANCER SIZE; CELL PROLIFERATION; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CLINICAL FEATURE; CUSHING SYNDROME; DISEASE MARKER; ESTROGEN RELEASE; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER METASTASIS; MALE; MASS FRAGMENTOGRAPHY; METABOLITE; MOLECULAR BIOLOGY; POSTOPERATIVE PERIOD; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; URINE;

17-ALPHA-HYDROXYPREGNENOLONE; 17-ALPHA-HYDROXYPROGESTERONE; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ADULT; CORTODOXONE; DEHYDROEPIANDROSTERONE; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM;

EID: 79960974868     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K11E-026     Document Type: Article

References (32)

1. Schulick RD, Brennan MF (1999) Adrenocortical carcinoma. World J Urol 17: 26-34.
2. Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Ali A, Giovagnetti M, Opocher G, Angeli A (2000) A survey on adrenal incidentaloma in Italy. J Clin Endocrinol Metab 85: 637-644.
3. Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein SR (2004) The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev 25: 309-340.
4. Fassnacht M, Allolio B (2009) Clinical management of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab 23: 273-289.
5. Libè R, Fratticci A, Bertherat J (2007) Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer 14: 13-28.
6. Weiss LM (1984) Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Path 8: 163-169.
7. Arola J, Salmenkivi K, Liu J, Kahri AI, Heikkila P (2000) p53 and Ki67 in adrenocortical tumors. Endocr Res 26: 861-865.
8. Kikuchi E, Yanaihara H, Nakashima J, Homma K, Ohigashi T, Asakura H, Tachibana M, Shibata H, Saruta T, Murai M (2000) Urinary steroid profile in adrenocortical tumors. Biomed Pharmacother 54 (Suppl 1): 194-197.
9. Homma K, Hasegawa T, Masumoto M, Takeshita E, Watanabe K, Chiba H, Kurosawa T, Takahashi T, Matsuo N (2003) Reference values for urinary steroids in Japanese newborn infants: gas chromatography/mass spectrometry in selected ion monitoring. Endocr J 50: 783-792.
10. Sasano H, Miyazaki S, Sawai T, Sasano N, Nagura H, Funahashi H, Aiba M, Demura H (1992) Primary pigmented nodular adrenocortical disease (PPNAD): immunohistochemical and in situ hybridization analysis of steroidogenic enzymes in eight cases. Mod Pathol 5: 23-29.
11. Fukai N, Hirono Y, Yoshimoto T, Doi M, Ohtsuka Y, Homma K, Shibata H, Sasano H, Hirata Y (2006) A ase of estrogen-secreting adrenocortical carcinoma with subclinical Cushing's syndrome. Endocr J 53: 237-245.
12. Sasano H, Suzuki T, Nagura H, Nishikawa T (1993) Steroidogenesis in human adrenocortical carcinoma: biochemical activities, immunohistochemistry, and in situ hybridization of steroidogenic enzymes and histopathologic study in nine cases. Hum Pathol 24: 397-404.
13. Grumbach MM, Biller BM, Braunstein GD, Campbell KK, Carney JA, Godley PA, Harris EL, Lee JK, Oertel YC, Posner MC, Schlechte JA, Wieand HS (2003) Management of the clinically inapparent adrenal mass ("incidentaloma"). Ann Intern Med 138: 424-429.
14. Lau J, Balk E, Rothberg M, Ioannidis JP, DeVine D, Chew P, Kupelnick B, Miller K (2002) Management of clinically inapparent adrenal mass. Evid Rep Technol Assess (Summ) 56: 1-5.
15. Schmitt A, Saremaslani P, Schmid S, Rousson V, Montani M, Schmid DM, Heitz PU, Komminoth P, Perren A (2006) IGFII and MIB1 immunohistochemistry is helpful for the differentiation of benign from malignant adrenocortical tumours. Histopathology 49: 298-307.
16. Stojadinovic A, Brennan MF, Hoos A, Omeroglu A, Leung DH, Dudas ME, Nissan A, Cordon-Cardo C, Ghossein RA (2003) Adrenocortical adenoma and carcinoma: histopathological and molecular comparative analysis. Mod Pathol 16: 742-751.
17. Sasano H, Suzuki T, Moriya T (2006) Recent advances in histopathology and immunohistochemistry of adrenocortical carcinoma. Endocr Pathol 17: 345-354.
18. Gröndal S, Eriksson B, Hagenäs L, Werner S, Curstedt T (1990) Steroid profile in urine: a useful tool in the diagnosis and follow up of adrenocortical carcinoma. Acta Endocrinol (Copenh)122: 656-663.
19. Abiven G, Coste J, Groussin L, Anract P, Tissier F, Legmann P, Dousset B, Bertagna X, Bertherat J (2006) Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab 91: 2650-2655.
20. Erickson LA, Jin L, Sebo TJ, Lohse C, Pankratz VS, Kendrick ML, van Heerden JA, Thompson GB, Grant CS, Lloyd RV (2001) Pathologic features and expression of insulin-like growth factor-2 in adrenocortical neoplasms. Endocr Pathol 12: 429-435.
21. Gicquel C, Raffin-Sanson ML, Gaston V, Bertagna X, Plouin PF, Schlumberger M, Louvel A, Luton JP, Le Bouc Y (1997) Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. J Clin Endocrinol Metab 82: 2559-2565.
22. Gicquel C, Bertagna X, Schneid H, Francillard-Leblond M, Luton JP, Girard F, le Bouc Y (1994) Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. J Clin Endocrinol Metab 78: 1444-1453.
23. Boulle N, Logié A, Gicquel C, Perin L, le Bouc Y (1998) Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors. J Clin Endocrinol Metab 83: 1713-1720.
24. Ilvesmäki V, Kahri AI, Miettinen PJ, Voutilainen R (1993) Insulin-like growth factors (IGFs) and their receptors in adrenal tumors: high IGF-II expression in functional adrenocortical carcinomas. J Clin Endocrinol Metab 77: 852-858.
25. Soon PS, Gill AJ, Benn DE, Clarkson A, Robinson BG, McDonald KL, Sidhu SB (2009) Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas. Endocr Relat Cancer 16: 573-583.
26. Logie A, Boulle N, Gaston V, Perin L, Boudou P, Le Bouc Y, Gicquel C (1999) Autocrine role of IGF-II in proliferation of human adrenocortical carcinoma NCI H295R cell line. J Mol Endocrinol 23: 23-32.
27. Fottner C, Hoeflich A, Wolf E, Weber MM (2004) Role of the insulin-like growth factor system in adrenocortical growth control and carcinogenesis. Horm Metab Res 36: 397-405.
28. Soon PS, McDonald KL, Robinson BG, Sidhu SB (2008) Molecular markers and the pathogenesis of adrenocortical cancer. Oncologist 13: 548-561.
29. Gicquel C, Bertagna X, Gaston V, Coste J, Louvel A, Baudin E, Bertherat J, Chapuis Y, Duclos JM, Schlumberger M, Plouin PF, Luton JP, Le Bouc Y (2001) Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res 61: 6762-6767.
30. Boulle N, Baudin E, Gicquel C, Logié A, Bertherat J, Penfornis A, Bertagna X, Luton JP, Schlumberger M, Le Bouc Y (2001) Evaluation of plasma insulin-like growth factor binding protein-2 as a marker for adrenocortical tumors. Eur J Endocrinol 144: 29-36.
31. de Fraipont F, El Atifi M, Cherradi N, Le Moigne G, Defaye G, Houlgatte R, Bertherat J, Bertagna X, Plouin PF, Baudin E, Berger F, Gicquel C, Chabre O, Feige JJ (2005) Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy. J Clin Endocrinol Metab 90: 1819-1829.
32. Ikushima H, Miyazono K (2010) TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer 10: 415-424.